Strongbridge Biopharma Plc [SBBP]

Source: 

Company Overview

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (the FDA) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.